{"id":90587,"date":"2026-05-12T22:38:09","date_gmt":"2026-05-13T04:38:09","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=90587"},"modified":"2026-05-20T11:37:51","modified_gmt":"2026-05-20T17:37:51","slug":"semaglutide-results-after-1-year-weight-loss-expectations","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/semaglutide-results-after-1-year-weight-loss-expectations\/","title":{"rendered":"Semaglutide Results After 1 Year: Realistic Weight Loss Expectations"},"content":{"rendered":"<h2>Introduction<\/h2>\n<p>A full year on semaglutide. Fifty-two weekly injections, several dose increases, and a fundamental shift in how your body relates to food. By 12 months, most patients have done the bulk of their weight loss, and the curve is bending into the maintenance zone.<\/p>\n<p>The STEP 1 (Wilding et al. 2021 NEJM) number to anchor expectations: average weight loss of 14.9 percent at week 68 on 2.4 mg. For a 240-pound starting weight, that&#8217;\\&#8221;s 36 pounds gone. For 180 pounds, 27 pounds.<\/p>\n<p>The trial reported 86 percent of patients hit at least 5 percent loss and 32 percent hit 20 percent or more. The distribution is wide, but the typical outcome is meaningful.<\/p>\n<p>At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you&#8217;re ready to see whether a personalized program is a fit for you.<\/p>\n<h2>What Is the Average Semaglutide Weight Loss at 1 Year?<\/h2>\n<p><strong>The STEP 1 average is 14.9 percent at week 68.<\/strong> At the 52-week mark, the average sits slightly lower, around 13 to 14 percent, since weight loss continued into weeks 52 to 68 for many patients.<\/p>\n<p>Quick Answer: STEP 1 reported 14.9 percent average weight loss at week 68 on 2.4 mg semaglutide<\/p>\n<p>For real-world expectation setting:<\/p>\n<ul>\n<li>Patients on 2.4 mg full schedule: 13 to 17 percent<\/li>\n<li>Patients on 1.7 mg long-term: 10 to 13 percent<\/li>\n<li>Patients with slower titration who reached 2.4 mg late: 11 to 14 percent<\/li>\n<\/ul>\n<p>Patients combining the drug with consistent strength training and protein-prioritized eating tend to land at the upper end of these ranges.<\/p>\n<h2>Why Is Year 1 Such an Important Milestone?<\/h2>\n<p><strong>Because it&#8217;\\&#8221;s where the metabolic set point begins shifting.<\/strong> Year 1 is when the brain&#8217;\\&#8221;s defended weight starts moving toward the new lower weight, which is the key difference between sustainable weight loss and short-term diet results.<\/p>\n<p>Follow-up data from STEP and SELECT trials suggests that patients who maintain weight loss for 12+ months have a substantially higher probability of long-term maintenance. The brain begins to defend the lower weight rather than aggressively pulling back to the original weight.<\/p>\n<p>Year 1 is also where lifestyle habits become automatic. Protein-first meals, regular strength training, and adequate sleep should be running on autopilot. The work shifts from active weight loss to chronic disease management.<\/p>\n<h2>What Dose Are Most Patients on at Year 1?<\/h2>\n<p><strong>Most are on 2.4 mg, the maximum approved dose for chronic weight management.<\/strong> About 80 to 85 percent of STEP 1 trial completers were on 2.4 mg by week 68.<\/p>\n<p>Some patients respond well to 1.7 mg and stay there. A small group needs to reduce due to side effects but maintains loss. The dose decision is individualized based on:<\/p>\n<ul>\n<li>Rate of continued weight loss<\/li>\n<li>Side effect tolerance<\/li>\n<li>Total remaining weight loss goal<\/li>\n<li>Cardiometabolic indications<\/li>\n<\/ul>\n<p>There&#8217;\\&#8221;s no benefit to running higher doses than necessary.<\/p>\n<h2>How Does Weight Loss Curve Through Year 1?<\/h2>\n<p>A typical semaglutide year looks like this:<\/p>\n<ul>\n<li>Months 1 to 3: 7 to 9 percent (rapid early loss)<\/li>\n<li>Months 4 to 6: 3 to 5 percent additional (steady)<\/li>\n<li>Months 7 to 9: 2 to 4 percent additional (slowing)<\/li>\n<li>Months 10 to 12: 1 to 2 percent additional (plateau approaching)<\/li>\n<\/ul>\n<p>By month 12, most patients are losing 0.25 to 0.75 pounds per week. Some have fully plateaued. Others continue to lose slowly through month 18.<\/p>\n<p>The slowdown is biological. Smaller bodies need fewer calories, and counter-regulatory hormones intensify as fat stores shrink. The drug doesn&#8217;\\&#8221;t lose effectiveness, but the math of weight loss changes.<\/p>\n<h2>What Predicts a Strong Year 1 Result?<\/h2>\n<p>Several factors emerged from STEP 1 analysis:<\/p>\n<ol>\n<li>Early response (5+ percent at week 12 strongly predicts 15+ percent at year 1)<\/li>\n<li>Reaching 2.4 mg by week 17 to 20<\/li>\n<li>Adherence to weekly dosing without long gaps<\/li>\n<li>Resistance training (preserves lean mass, supports metabolic rate)<\/li>\n<li>Adequate protein intake (0.7 to 1 gram per pound of target weight)<\/li>\n<li>7+ hours of sleep per night<\/li>\n<\/ol>\n<p>Patients hitting all six markers typically deliver 16 to 20 percent total loss. Missing several of these drops average outcomes into the 9 to 12 percent range.<\/p>\n<h2>What Cardiometabolic Improvements Show up by Year 1?<\/h2>\n<p>Often substantial. The typical semaglutide patient at 1 year shows:<\/p>\n<ul>\n<li>HbA1c drop of 1 to 1.5 percentage points in patients with prediabetes\/diabetes<\/li>\n<li>Systolic BP drop of 7 to 10 mmHg<\/li>\n<li>LDL cholesterol decrease of 8 to 15 percent<\/li>\n<li>Triglyceride decrease of 25 to 35 percent<\/li>\n<li>C-reactive protein (inflammation) reduction of 35 to 50 percent<\/li>\n<\/ul>\n<p>The SELECT trial (Lincoff et al. 2023 NEJM) showed 20 percent reduction in major adverse cardiovascular events over 3 years in patients with established cardiovascular disease. The FLOW trial (Perkovic et al. 2024 NEJM) showed 24 percent reduction in kidney and cardiovascular death in patients with chronic kidney disease.<\/p>\n<p>These benefits often justify long-term use independent of weight loss alone.<\/p>\n<p>Key Takeaway: Roughly 70 percent of weight loss occurs in the first 6 months; the rest comes slowly<\/p>\n<h2>What Does Year 2 Look Like?<\/h2>\n<p><strong>Mostly maintenance with slow additional losses.<\/strong> The STEP 1 extension data showed that patients continuing semaglutide through year 2 maintain their losses and often add another 1 to 3 percent.<\/p>\n<p>STEP 4 (Rubino et al. 2021 JAMA) compared continuing vs discontinuing semaglutide at week 20. Patients who continued lost an additional 8 percent over the next 48 weeks. Patients who switched to placebo regained 7 percent.<\/p>\n<p>Discontinuation typically leads to substantial regain. STEP 1 follow-up showed that patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year.<\/p>\n<h2>How Long Should You Stay on Semaglutide?<\/h2>\n<p><strong>The framing in obesity medicine has shifted.<\/strong> Semaglutide is now generally viewed as long-term therapy similar to medications for hypertension or hyperlipidemia, rather than a short-term weight loss tool.<\/p>\n<p>Reasons to continue past year 1:<\/p>\n<ul>\n<li>Goal weight not yet reached<\/li>\n<li>Cardiovascular disease indication (SELECT)<\/li>\n<li>Chronic kidney disease (FLOW)<\/li>\n<li>Type 2 diabetes<\/li>\n<li>Strong preference to maintain the loss<\/li>\n<li>Tolerable side effects at a sustainable dose<\/li>\n<\/ul>\n<p>Reasons to reduce or stop:<\/p>\n<ul>\n<li>Adverse effects outweighing benefit<\/li>\n<li>Pregnancy planning (semaglutide should be stopped 2 months prior)<\/li>\n<li>Cost barriers<\/li>\n<li>Goal weight achieved with high confidence in sustaining<\/li>\n<\/ul>\n<p>TrimRx providers typically build year 1 to year 2 transition plans based on goals and tolerance, with a free assessment quiz used to update treatment plans annually.<\/p>\n<h2>What If Your Year 1 Results Are Below Average?<\/h2>\n<p><strong>Below 8 percent loss at year 1 on 2.4 mg is uncommon but does happen.<\/strong> Things to address:<\/p>\n<ul>\n<li>Is the dose actually 2.4 mg? Some patients held at 1.0 or 1.7 mg longer than expected.<\/li>\n<li>Are weekly doses being missed?<\/li>\n<li>Is there an underlying medical issue (untreated hypothyroidism, sleep apnea, Cushing&#8217;\\&#8221;s, PCOS)?<\/li>\n<li>Are concurrent medications interfering?<\/li>\n<li>Is the diet structure providing enough protein and not too many liquid calories?<\/li>\n<\/ul>\n<p>In trial data, true non-responders (less than 5 percent loss at 1 year despite 2.4 mg dosing) made up less than 10 percent of patients. Most apparent non-response is actually under-dosing, behavioral, or driven by addressable medical factors.<\/p>\n<h2>How Do You Maintain After the Active Loss Phase?<\/h2>\n<p>Maintenance protocols vary, but the core principles are stable:<\/p>\n<ul>\n<li>Continue weekly dosing at the lowest effective dose<\/li>\n<li>Maintain protein intake (lean mass is harder to defend than fat mass is to lose)<\/li>\n<li>Keep strength training to preserve muscle and metabolic rate<\/li>\n<li>Monitor weight weekly to catch drift early<\/li>\n<li>Re-engage provider check-ins every 3 to 6 months<\/li>\n<\/ul>\n<p>The shift is from active weight loss to chronic disease management. The drug is doing maintenance work, and the lifestyle changes from year 1 carry through.<\/p>\n<h2>Should You Switch to Tirzepatide at Year 1?<\/h2>\n<p><strong>A reasonable question for patients who plateaued early and haven&#8217;\\&#8221;t reached their goal.<\/strong> SURMOUNT-5 showed tirzepatide produced 6.5 percentage points more weight loss than semaglutide over 72 weeks.<\/p>\n<p>Switching is increasingly common in clinical practice. The transition typically involves stopping semaglutide for 1 to 2 weeks then starting tirzepatide at 2.5 mg with standard titration.<\/p>\n<p>For patients with cardiovascular or kidney indications, staying on semaglutide remains the better choice unless weight loss is critically inadequate.<\/p>\n<p>Bottom line: Cardiometabolic markers (BP, A1c, lipids, CV events) often normalize by year 1<\/p>\n<h2>FAQ<\/h2>\n<h3>Is 35 Pounds in 1 Year a Good Semaglutide Result?<\/h3>\n<p>For a 250-pound starting weight, 35 pounds is 14 percent, right at the STEP 1 average. For 200 pounds, 35 pounds is 17.5 percent, in the top third. For 320 pounds, 35 pounds is 11 percent, somewhat below average.<\/p>\n<h3>Will Weight Loss Continue Into Year 2?<\/h3>\n<p>Usually slowly. Most patients add another 2 to 4 percent in year 2 if they continue, then plateau. A small group keeps losing slowly into year 3.<\/p>\n<h3>Should I Drop the Dose at Year 1?<\/h3>\n<p>Only if you&#8217;\\&#8221;ve hit goal weight and stabilized for 3+ months. Premature dose reduction tends to cause weight creep.<\/p>\n<h3>What About Long-term Safety?<\/h3>\n<p>STEP 1 followed patients for 68 weeks, SELECT for over 3 years. Safety has been strong. Pancreatitis, severe GI events, and other serious adverse effects remain uncommon. Routine monitoring is appropriate.<\/p>\n<h3>Can I Take a Break From Injections at Year 1?<\/h3>\n<p>Generally not advisable. STEP 4 showed clear regain after stopping. Weekly dosing is the standard, with no clinical benefit to drug holidays.<\/p>\n<h3>What If I&#8217;\\&#8221;ve Regained Weight at Year 1?<\/h3>\n<p>Often a sign of dose drift or behavioral slippage. A check-in with your provider, return to careful protein tracking, and confirmation of injection technique usually addresses it.<\/p>\n<h3>Should I Get a DEXA Scan at Year 1?<\/h3>\n<p>Worth doing if available. DEXA shows lean mass and bone density, both of which matter for long-term function. A 1-year DEXA also gives a baseline for ongoing maintenance.<\/p>\n<p><strong>Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A full year on semaglutide. Fifty-two weekly injections, several dose increases, and a fundamental shift in how your body relates to food.<\/p>\n","protected":false},"author":11,"featured_media":93321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Semaglutide Results After 1 Year: Realistic Weight Loss Expectations","_yoast_wpseo_metadesc":"A full year on semaglutide. Fifty-two weekly injections, several dose increases, and a fundamental shift in how your body relates to food.","_yoast_wpseo_focuskw":"semaglutide results after","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[42,46,56],"class_list":["post-90587","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic","tag-results","tag-semaglutide","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90587"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90587\/revisions"}],"predecessor-version":[{"id":91845,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90587\/revisions\/91845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93321"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}